Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells (Articolo in rivista) (literal)

Anno

• 2013-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

• 10.1371/journal.pone.0061603 (literal)

Alternative label

• Carmelo Carlo-Stella, Silvia L. Locatelli, Arianna Giacomini, Loredana Cleris, Elena Saba, Marco Righi, Anna Guidetti, Alessandro M. Gianni (2013)
  Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells
  in PloS one; Public Library of Science, San Francisco (Stati Uniti d'America)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Carmelo Carlo-Stella, Silvia L. Locatelli, Arianna Giacomini, Loredana Cleris, Elena Saba, Marco Righi, Anna Guidetti, Alessandro M. Gianni (literal)

Pagina inizio

• e61603 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 8 (literal)

Rivista

• PloS one (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

• 4 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Carmelo Carlo-Stella, Silvia L. Locatelli, Arianna Giacomini Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milano, Italy Carmelo Carlo-Stella, Silvia L. Locatelli, Arianna Giacomini, Elena Saba Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy Loredana Cleris Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy Marco Righi National Research Council, Institute of Neuroscience, Milan, Italy Anna Guidetti, Alessandro M. Gianni Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy Anna Guidetti, Alessandro M. Gianni Department of Medical Physiopathology and Transplants, University of Milano, Milano, Italy (literal)

Titolo

• Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells (literal)

Abstract

• The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines. In vitro, sorafenib significantly decreased cell proliferation and phosphorylation levels of MAPK and PI3K/Akt pathways while increased apoptotic cell death. In vivo, sorafenib treatment resulted in a cytostatic rather than cytotoxic effect on tumor cell growth associated with a limited inhibition of tumor volumes. However, sorafenib induced an average 50% reduction of tumor vessel density and a 2-fold increase of necrotic areas. Upon sorafenib treatment, endothelial and tumor cells from SU-DHL-4V, Granta-519, and KMS-11 nodules showed a potent inhibition of either phospho-ERK or phospho-AKT, whereas a concomitant inhibition of phospho-ERK and phospho-AKT was only observed in HD-MyZ nodules. In conclusion, sorafenib affects the growth of lymphoid cell lines by triggering antiangiogenic mechanism(s) and directly targeting tumor cells. (literal)

Editore

• Public Library of Science (Editore)

Prodotto di

• Istituto di neuroscienze (IN) (Istituto)
• Farmacologia Cellulare e Molecolare delle Cellule Nervose (ME.P02.007.001) (Modulo)

Autore CNR

• MARCO GIOVANNI ENEA RIGHI (Persona)

Incoming links:

Autore CNR di

• MARCO GIOVANNI ENEA RIGHI (Persona)

Prodotto

• Istituto di neuroscienze (IN) (Istituto)
• Farmacologia Cellulare e Molecolare delle Cellule Nervose (ME.P02.007.001) (Modulo)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• PloS one (Rivista)

Editore di

• Public Library of Science (Editore)